Cyxone AB (publ) (4CX.F)
- Previous Close
0.0048 - Open
0.0030 - Bid 0.0112 x --
- Ask 0.0190 x --
- Day's Range
0.0030 - 0.0054 - 52 Week Range
0.0001 - 0.0539 - Volume
10,000 - Avg. Volume
18,685 - Market Cap (intraday)
2.641M - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, Sweden.
www.cyxone.comRecent News: 4CX.F
Performance Overview: 4CX.F
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4CX.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4CX.F
Valuation Measures
Market Cap
2.64M
Enterprise Value
248.04k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.43
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.33%
Return on Equity (ttm)
-53.52%
Revenue (ttm)
5.15M
Net Income Avi to Common (ttm)
-22.99M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
17.53M
Total Debt/Equity (mrq)
2.20%
Levered Free Cash Flow (ttm)
-17.28M
Research Analysis: 4CX.F
Company Insights: 4CX.F
4CX.F does not have Company Insights